| Authors: |
Camidge DR; University of Colorado Cancer Center, Aurora, CO., Barlesi F; Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Inserm U911 CRO2, Marseille, France.; Medical Oncology Department, Gustave Roussy, Villejuif, France., Goldman JW; David Geffen School of Medicine at UCLA, Los Angeles, CA., Morgensztern D; Washington University School of Medicine, St Louis, MO., Heist R; Massachusetts General Hospital Cancer Center, Boston, MA., Vokes E; University of Chicago Medicine, Chicago, IL., Spira A; Virginia Cancer Specialists Research Institute, Fairfax, VA., Angevin E; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France., Su WC; National Cheng Kung University Hospital, Tainan, Taiwan., Hong DS; The University of Texas MD Anderson Cancer Center, Houston, TX., Strickler JH; Duke University Medical Center, Durham, NC., Motwani M; AbbVie Inc, North Chicago, IL., Dunbar M; AbbVie Inc, North Chicago, IL., Parikh A; AbbVie Inc, Redwood City, CA., Noon E; AbbVie Inc, North Chicago, IL., Blot V; AbbVie Inc, North Chicago, IL., Wu J; AbbVie Inc, North Chicago, IL., Kelly K; University of California Davis Comprehensive Cancer Center, Sacramento, CA. |
